<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02451579</url>
  </required_header>
  <id_info>
    <org_study_id>PDT-2015-01</org_study_id>
    <nct_id>NCT02451579</nct_id>
  </id_info>
  <brief_title>A Clinical Trial Evaluating the Role of Systemic Antihistamine Therapy in the Reduction of Adverse Effects Associated With Topical 5-aminolevulinic Acid Photodynamic Therapy</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Prospective Clinical Trial Evaluating the Role of Systemic Antihistamine Therapy in the Reduction of Adverse Effects Associated With Topical 5-aminolevulinic Acid Photodynamic Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Goldman, Butterwick, Fitzpatrick and Groff</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>DUSA Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Goldman, Butterwick, Fitzpatrick and Groff</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A double-blind, placebo controlled study conducted at a single study site. Evaluating the&#xD;
      role of systemic antihistamine therapy in the reduction of adverse effects associated with&#xD;
      topical 5-aminolevulinic acid photodynamic therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Localized Skin Response</measure>
    <time_frame>Up to day 180</time_frame>
    <description>Localized Skin Response consisting of erythema, edema, crusting, exudation, Vesiculation/Pustulation and erosion/ ulceration Investigator evaluated on a standardized scale</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Actinic Keratoses</condition>
  <arm_group>
    <arm_group_label>Cetirizine Hydrochloride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prophylactic use of cetirizine hydrochloride prior to and after Topical 5-aminolevulinic Acid Photodynamic Therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Prophylactic use of placebo prior to and after Topical 5-aminolevulinic Acid Photodynamic Therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antihistamine Cetirizine Hydrochloride</intervention_name>
    <description>Prophylactic use of antihistamine prior to and following topical 5-aminolevulonic acid photodynamic therapy</description>
    <arm_group_label>Cetirizine Hydrochloride</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Use of placebo prior to and following topical 5-aminolevulonic acid photodynamic therapy</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18&#xD;
&#xD;
          -  Subjects with 5-20 actinic keratosis of the face&#xD;
&#xD;
          -  Patients undergoing photodynamic therapy (PDT) to the face for AK with&#xD;
             5-aminolevulinic acid (ALA) activated by blue light.&#xD;
&#xD;
          -  Must be willing to give and sign a HIPPA form, photo consent and informed consent&#xD;
             form.&#xD;
&#xD;
          -  Must be willing to comply with study dosing and complete the entire course of the&#xD;
             study.&#xD;
&#xD;
          -  Female patients will be either of non-childbearing potential defined as:&#xD;
&#xD;
               1. Having no uterus&#xD;
&#xD;
               2. No menses for at least 12 months.&#xD;
&#xD;
        Or;&#xD;
&#xD;
        (WOCBP) women of childbearing potential must agree to use an effective method of birth&#xD;
        control during the course of the study, such as:&#xD;
&#xD;
          1. Oral contraceptive pill, injection, implant, patch, vaginal ring, intrauterine device&#xD;
&#xD;
          2. Intrauterine coil&#xD;
&#xD;
          3. Bilateral tubal ligation&#xD;
&#xD;
          4. Barrier method used with an additional form of contraception (e.g., sponge, spermicide&#xD;
             or condom)&#xD;
&#xD;
          5. Abstinence (If practicing abstinence must agree to use barrier method described above&#xD;
             (d) if becomes sexually active).&#xD;
&#xD;
          6. Vasectomized partner g. Negative urine pregnancy test results Baseline prior to study&#xD;
             entry (if applicable)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of incompletely healed wound in treatment area&#xD;
&#xD;
          -  Presence of known or suspected BCC or SCC in treatment area&#xD;
&#xD;
          -  Previous PDT or treatment of the face with any topical cytotoxic or immunomodulatory&#xD;
             agent for AKs within the past 6 months&#xD;
&#xD;
          -  Co-existing potentially confounding skin condition within treatment area (e.g. eczema,&#xD;
             psoriasis, XP, rosacea) at investigator's discretion&#xD;
&#xD;
          -  Presence of tattoo and/or scar in the treatment area that in the investigators opinion&#xD;
             would interfere with study assessments&#xD;
&#xD;
          -  Subjects with known photosensitivity or taking photosensitizing medications listed&#xD;
             below:&#xD;
&#xD;
               1. Oral diabetes medicines&#xD;
&#xD;
               2. Griseofulvin&#xD;
&#xD;
               3. Thiazide diuretics&#xD;
&#xD;
               4. Sulfonylureas&#xD;
&#xD;
               5. Phenothiazines&#xD;
&#xD;
               6. Tetracycline's&#xD;
&#xD;
               7. St. John's Wort&#xD;
&#xD;
          -  Use of oral/topical retinoids within 1 month of Baseline&#xD;
&#xD;
          -  Subjects with a history of sensitivity to porphyrins&#xD;
&#xD;
          -  Subjects with recently excessive exposure of the treatment area to sunlight or&#xD;
             artificial UV light (e.g.: use of tanning beds/booths and/or sunbathing) or&#xD;
             expectations of tanning during the time of the study&#xD;
&#xD;
          -  Female subjects who are pregnant, nursing an infant or planning a pregnancy during the&#xD;
             study [throughout the course of the study&#xD;
&#xD;
          -  Presence or evidence of any conditions that in the opinion of the investigator might&#xD;
             impede the subject's ability to give consent or comply with protocol requirements.&#xD;
&#xD;
          -  Current participation or participation within 30 days prior to the start of this study&#xD;
             in a drug or other investigational research study&#xD;
&#xD;
          -  History of non-compliance with clinical research protocols&#xD;
&#xD;
          -  Ablative laser resurfacing to on their face within 12 months&#xD;
&#xD;
          -  Non-ablative laser or light procedures to their face within the past 3 months&#xD;
&#xD;
          -  Microdermabrasion (light or medium skin peel) treatment on their face within the past&#xD;
             30 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitchel P Goldman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cosmetic Laser Dermatology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cosmetic Laser Dermatology</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>May 12, 2015</study_first_submitted>
  <study_first_submitted_qc>May 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2015</study_first_posted>
  <last_update_submitted>February 27, 2017</last_update_submitted>
  <last_update_submitted_qc>February 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Actinic Keratoses</keyword>
  <keyword>Photodynamic Therapy</keyword>
  <keyword>PDT</keyword>
  <keyword>Blue Light</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis, Actinic</mesh_term>
    <mesh_term>Keratosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetirizine</mesh_term>
    <mesh_term>Histamine Antagonists</mesh_term>
    <mesh_term>Histamine H1 Antagonists</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>May 1, 2019</submitted>
    <returned>May 22, 2019</returned>
    <submitted>August 15, 2019</submitted>
    <returned>September 4, 2019</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

